STALEY CAPITAL ADVISERS’s Anixa Biosciences ANIX Stock Holding History

STALEY CAPITAL ADVISERS’s Portfolio ANIX Stock Details ANIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$29.3K	Hold	10,000	–	–	﹤0.01%	199
2026 Q2	$28K	Hold	10,000	–	–	﹤0.01%	192
2026 Q1	$25.8K	Hold	10,000	–	–	﹤0.01%	183
2025 Q4	$31.2K	Hold	10,000	–	–	﹤0.01%	191
2025 Q3	$33K	Hold	10,000	–	–	﹤0.01%	196
2025 Q2	$33K	Hold	10,000	–	–	﹤0.01%	191
2025 Q1	$28.6K	Hold	10,000	–	–	﹤0.01%	188
2024 Q4	$23.2K	Hold	10,000	–	–	﹤0.01%	178
2024 Q3	$31.5K	Hold	10,000	–	–	﹤0.01%	183
2024 Q2	$22.1K	Hold	10,000	–	–	﹤0.01%	181
2024 Q1	$31.2K	Buy	+10,000	New	+$39.9K	﹤0.01%	183

Other funds holding ANIX

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

D.A. Davidson & Co Great Falls, Montana $18.6B AUM 17.65% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

LPL Financial San Diego, California $468B AUM 17.69% 1-Year Est. Return

CoreCap Advisors Southfield, Michigan $3.48B AUM 21.43% 1-Year Est. Return

STALEY CAPITAL ADVISERS's ANIX Position: Q3 2026 in Review

STALEY CAPITAL ADVISERS held its Anixa Biosciences (ANIX) position steady in Q3 2026 at 10,000 shares worth $29.3K. The position accounts for ﹤0.01% of the portfolio, ranked #199.

STALEY CAPITAL ADVISERS first reported a position in ANIX in Q1 2024 and has held it in 11 quarters since. The position peaked at $33K in Q3 2025. 53 funds tracked by Wall St. Rank hold ANIX as of Q3 2026.

STALEY CAPITAL ADVISERS held 10,000 shares of Anixa Biosciences worth $29.3K as of Q3 2026.
STALEY CAPITAL ADVISERS left its Anixa Biosciences share count unchanged in Q3 2026.
Anixa Biosciences made up ﹤0.01% of STALEY CAPITAL ADVISERS's portfolio in Q3 2026, its #199 holding.
STALEY CAPITAL ADVISERS first reported a position in Anixa Biosciences in Q1 2024 and has held it in 11 quarters since.
STALEY CAPITAL ADVISERS's Anixa Biosciences position peaked at $33K in Q3 2025.
53 funds tracked by Wall St. Rank held Anixa Biosciences as of Q3 2026.

Based on STALEY CAPITAL ADVISERS's 13F filing for Q3 2026, filed 6 Nov 2026.